The course of metastatic prostate cancer under treatment
The first-line management of metastatic prostate cancer is hormonal therapy. However, resistance to this treatment will emerge within an average of 24 months. Our purpose was to determine the course of metastatic prostate cancer under treatment.
Main Authors: | Demir, Aslan, Cecen, Kursat, Karadag, Mert Ali, Kocaaslan, Ramazan, Turkeri, Levent |
---|---|
Format: | Online |
Language: | English |
Published: |
Springer International Publishing
2014
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320210/ |
Similar Items
-
Small cell carcinoma of the prostate presenting with skin metastasis: a case report
by: Cecen, Kursat, et al.
Published: (2014) -
The role of transcavitary ultrasonography in diagnosis and staging of nonmuscle-ınvasive bladder cancer: a prospective non-randomized clinical study
by: Oktem, Gultekin Cagri, et al.
Published: (2014) -
Flexible Ureterorenoscopy versus Extracorporeal Shock Wave Lithotripsy for the treatment of upper/middle calyx kidney stones of 10–20 mm: a retrospective analysis of 174 patients
by: Cecen, Kursat, et al.
Published: (2014) -
Erratum to: Flexible Ureterorenoscopy versus Extracorporeal Shock Wave Lithotripsy for the treatment of upper/middle calyx kidney stones of 10–20 mm: a retrospective analysis of 174 patients
by: Cecen, Kursat, et al.
Published: (2016) -
Gastrointestinal Complications of Laparoscopic/Robot-Assisted Urologic Surgery and a Review of the Literature
by: Karadag, Mert Ali, et al.
Published: (2015)